Vor Biopharma (NASDAQ:VOR) Now Covered by JPMorgan Chase & Co.

JPMorgan Chase & Co. started coverage on shares of Vor Biopharma (NASDAQ:VOR) in a report issued on Tuesday morning, MarketBeat.com reports. The brokerage issued an overweight rating and a $43.00 target price on the stock.

Several other analysts also recently weighed in on VOR. Zacks Research upgraded Vor Biopharma from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th. Baird R W upgraded shares of Vor Biopharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, October 8th. Robert W. Baird raised shares of Vor Biopharma from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $20.00 to $64.00 in a research note on Wednesday, October 15th. Finally, HC Wainwright dropped their target price on Vor Biopharma from $55.00 to $32.00 and set a “buy” rating on the stock in a research report on Friday, November 14th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Vor Biopharma has a consensus rating of “Moderate Buy” and a consensus target price of $68.86.

Vor Biopharma Price Performance

VOR opened at $10.72 on Tuesday. The business’s fifty day moving average price is $20.00. The stock has a market cap of $111.60 million, a P/E ratio of -0.03 and a beta of 2.08. Vor Biopharma has a 52 week low of $2.62 and a 52 week high of $65.80.

Insiders Place Their Bets

In other news, Director Ra Capital Management, L.P. sold 260,859 shares of the stock in a transaction on Friday, October 17th. The stock was sold at an average price of $29.39, for a total transaction of $7,666,646.01. Following the completion of the sale, the director owned 15,104 shares in the company, valued at approximately $443,906.56. This represents a 94.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Reprogrammed Interchange Llc sold 447,278 shares of the firm’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $1.54, for a total value of $688,808.12. Following the completion of the sale, the insider directly owned 32,781,209 shares of the company’s stock, valued at $50,483,061.86. The trade was a 1.35% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 2,193,681 shares of company stock worth $52,596,733. Insiders own 0.45% of the company’s stock.

Hedge Funds Weigh In On Vor Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of VOR. OMERS ADMINISTRATION Corp purchased a new position in shares of Vor Biopharma in the first quarter worth $100,000. Goldman Sachs Group Inc. increased its position in shares of Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after acquiring an additional 58,247 shares during the period. Jane Street Group LLC purchased a new position in Vor Biopharma in the 1st quarter worth $140,000. XTX Topco Ltd acquired a new stake in Vor Biopharma during the 2nd quarter worth about $66,000. Finally, Ariose Capital Management Ltd purchased a new stake in Vor Biopharma during the 3rd quarter valued at about $5,368,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.